Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study.

IF 2.9 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Discover. Oncology Pub Date : 2025-07-12 DOI:10.1007/s12672-025-03120-y

Chia-Ching Chang, Yi-Liang Lee, Chih-Hsiang Yin, Cheng-Chang Chang, Yi-Hsin Lin

{"title":"Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study.","authors":"Chia-Ching Chang, Yi-Liang Lee, Chih-Hsiang Yin, Cheng-Chang Chang, Yi-Hsin Lin","doi":"10.1007/s12672-025-03120-y","DOIUrl":null,"url":null,"abstract":"Background: Cancer related fatigue (CRF) is a common and debilitating side effect among gynecologic cancer patients undergoing chemotherapy. Astragalus polysaccharides (PG2), an immunomodulatory drug, has shown promise in relieving CRF. This study aimed to evaluate the effectiveness of PG2 in managing CRF in gynecologic cancer patients.Methods: This retrospective cohort study was performed at the Department of Obstetrics & Gynecology, Tri-Service General Hospital from December 2015 to December 2022. Of 53 patients included, 40 received PG2 with chemotherapy, while 13 received chemotherapy alone. Outcomes included CRF severity and HRQL, assessed via Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-General 7 (FACT-G7), plus safety profiles.Results: PG2-treated patients showed a statistically significant reduction in CRF severity, as reflected by lower BFI (p < 0.001). The PG2 group showed trends toward improved HRQL and reduced appetite loss, though not statistically significant (p > 0.05). PG2's safety profile aligned with the control group, showing no increase in grade 3/4 toxicities.Conclusion: The study concludes that PG2 shows promise as an adjunct therapy in the management of CRF among patients with gynecologic cancer receiving chemotherapy. However, the findings highlight the need for additional prospective, randomized controlled trials to rule out the risk of bias and ascertain PG2's full therapeutic potential in oncology supportive care.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1322"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255631/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-03120-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cancer related fatigue (CRF) is a common and debilitating side effect among gynecologic cancer patients undergoing chemotherapy. Astragalus polysaccharides (PG2), an immunomodulatory drug, has shown promise in relieving CRF. This study aimed to evaluate the effectiveness of PG2 in managing CRF in gynecologic cancer patients.

Methods: This retrospective cohort study was performed at the Department of Obstetrics & Gynecology, Tri-Service General Hospital from December 2015 to December 2022. Of 53 patients included, 40 received PG2 with chemotherapy, while 13 received chemotherapy alone. Outcomes included CRF severity and HRQL, assessed via Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-General 7 (FACT-G7), plus safety profiles.

Results: PG2-treated patients showed a statistically significant reduction in CRF severity, as reflected by lower BFI (p < 0.001). The PG2 group showed trends toward improved HRQL and reduced appetite loss, though not statistically significant (p > 0.05). PG2's safety profile aligned with the control group, showing no increase in grade 3/4 toxicities.

Conclusion: The study concludes that PG2 shows promise as an adjunct therapy in the management of CRF among patients with gynecologic cancer receiving chemotherapy. However, the findings highlight the need for additional prospective, randomized controlled trials to rule out the risk of bias and ascertain PG2's full therapeutic potential in oncology supportive care.

查看原文本刊更多论文

黄芪多糖（PG2）缓解妇科癌症化疗引起的疲劳的疗效：一项回顾性队列研究。

背景：癌症相关性疲劳（CRF）是妇科癌症患者化疗过程中常见的令人衰弱的副作用。黄芪多糖（PG2）是一种免疫调节药物，在缓解慢性肾功能衰竭方面表现出良好的前景。本研究旨在评价PG2治疗妇科肿瘤患者慢性肾功能衰竭的有效性。方法：回顾性队列研究于2015年12月至2022年12月在三院总医院妇产科进行。纳入的53例患者中，40例接受PG2联合化疗，13例单独化疗。结果包括CRF严重程度和HRQL，通过简短疲劳量表（BFI）和癌症治疗功能评估（FACT-G7）以及安全性评估。结果：pg2治疗患者的CRF严重程度有统计学意义的降低，反映在较低的BFI （p 0.05）。PG2的安全性与对照组一致，未显示3/4级毒性增加。结论：该研究表明，PG2有望作为妇科癌症化疗患者治疗CRF的辅助疗法。然而，研究结果强调需要额外的前瞻性、随机对照试验来排除偏倚风险，并确定PG2在肿瘤支持治疗中的全部治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊